Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061211 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL12445298 | 0.87 | USP2 (0.48) | USP2SMN1; SMN2EPHX2HPGDRECQL | |
| SCHEMBL1604637 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL31343939 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL25216320 | 0.85 | USP2 (0.42) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL475749 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL30825786 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL30396068 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL31616252 | 0.83 | HPGD (0.41) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 | |
| SCHEMBL23579343 | 0.83 | USP2 (0.47) | USP2SMN1; SMN2EPHX2HDAC2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481774-B2 | Method for producing tetrafluoro compound | NIPPON SODA CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481774-B2 | Method for producing tetrafluoro compound | NIPPON SODA CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | NIPPON SODA CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | NIPPON SODA CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | F9, CA9, TAF9 | USP2 4138/4885SMN1; SMN2 3613/4885EPHX2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.